Older drugs no match against drug-resistant infections

As antibiotics lose their punch, a team of researchers at McMaster University discovered "old" drugs that doctors are turning to also have built-in problems in thwarting infectious diseases.

Gerard Wright, director of the Michael G. DeGroote Institute for Infectious Disease Research, examined rifampin ADP-ribosyltransferase (ARR), an enzyme that gives rise to resistance to rifampin, a 40-year-old drug used to treat tuberculosis and hospital-acquired infections, such as multi drug-resistant staphylococcus aureus (MRSA).

Wright and his team found that the gene coding the ARR enzyme is widespread in a variety of bacteria in the environment (outdoors, water, soil, streams, oceans) and hospitals and that it is equally effective blocking "old" antibiotics like rifampin as well as new versions of this drug recently introduced into the clinic.

This research shows that the effectiveness of re-using "old" drugs such as rifampin is hindered by resistant organisms that already exist in bacterial strains in hospitals and in soil in the broader community.

"Our work provides a blueprint on how to learn about these mechanisms and how we can use this knowledge to be more strategic on what new compounds to make and how to deploy them effectively," he said.

The research appears in the upcoming issue of the Proceedings of the National Academy of Sciences (PNAS).

Drug-resistant diseases are a growing problem. For example, MRSA rates in Canadian hospitals are now 10 times higher than in 1995, according to the Canadian Nosocomial Infection Surveillance Program which follows infection rates and trends in Canada.

Source: McMaster University

Related stories:

Older antibiotic gains new respect as potent treatment for tuberculosis
It has no current market, not even a prescription price. Its makers stopped commercial production years ago, because demand was so low. But an antibiotic long abandoned as a weak, low-dose treatment for tuberculosis (TB) may have found renewed purpose, this time as a potent, high-dose fighter against the most common and actively contagious form of the lung disease.
New antibiotic drug combo to speed up treatment of tuberculosis
A team of tuberculosis (TB) experts at Johns Hopkins and in Brazil have evidence that substituting the antibiotic moxifloxacin in the regimen of drugs used to treat the highly contagious form of lung disease could dramatically shorten the time needed to cure the illness from six months to four.
Treatment outcomes of patients with HIV and tuberculosis
In a retrospective study of 700 patients with culture-positive tuberculosis (TB), relapse rates were found to be significantly higher in HIV-infected patients compared to HIV-uninfected patients following a rifamycin-based regimen. Furthermore, TB relapse rates were higher in HIV-infected patients who received intermittent or standard 6-month therapy when compared to those receiving daily or longer treatment.

News discussion:

Medicine & Health news